---
figid: PMC4440880__3236f1
figlink: /pmc/articles/PMC4440880/figure/F1/
number: F1
caption: 'Activation and targeting of prosurvival pathways mediating FLT3 resistance.
  (A) The downstream effectors pERK, pAKt, pS6K, and pSTAT are not sufficiently inhibited
  despite FLT3 signaling blockade in sorafenib-resistant FLT3 cell lines harboring
  acquired point mutations in the tyrosine kinase domains. The MEK/ERK pathway likely
  plays a central role in this feedback modulation with smaller contributions from
  the PI3K/AKT and STAT5 pathways. Circulating blasts are dependent on FLT3 signaling
  for activation of the MEK/ERK pathways. Stromal cytokines may activate the MEK/ERK
  pathway in stromal leukemia blasts independent of FLT3-ITD signaling, such as through
  CXCL12/CXCR4 interactions, conferring resistance to the clinically available FLT3
  inhibitors. (B) Concomitant inhibition of CXCR4 (plerixafor), Pi3K (Pi3K inhibitors:
  BKM-120, IPI-145, BYL-719), MEK/ERK (PD0325901, trametinib, MEK-162, E6201), AKT/mTOR
  (mTOR inhibitors: CCI-779, everolimus), NF-κB inhibitors (early clinical trials),
  PiM-kinase inhibitors (early clinical trials), and FLT3 produces a synergistic effect
  in sorafenib-resistant cell lines.'
pmcid: PMC4440880
papertitle: Secondary mutations as mediators of resistance to targeted therapy in
  leukemia.
reftext: Naval Daver, et al. Blood. 2015 May 21;125(21):3236-3245.
pmc_ranked_result_index: '94017'
pathway_score: 0.817548
filename: 3236f1.jpg
figtitle: Activation and targeting of prosurvival pathways mediating FLT3 resistance
year: '2015'
organisms:
- Homo sapiens
ndex: 1ca582c8-df09-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4440880__3236f1.html
  '@type': Dataset
  description: 'Activation and targeting of prosurvival pathways mediating FLT3 resistance.
    (A) The downstream effectors pERK, pAKt, pS6K, and pSTAT are not sufficiently
    inhibited despite FLT3 signaling blockade in sorafenib-resistant FLT3 cell lines
    harboring acquired point mutations in the tyrosine kinase domains. The MEK/ERK
    pathway likely plays a central role in this feedback modulation with smaller contributions
    from the PI3K/AKT and STAT5 pathways. Circulating blasts are dependent on FLT3
    signaling for activation of the MEK/ERK pathways. Stromal cytokines may activate
    the MEK/ERK pathway in stromal leukemia blasts independent of FLT3-ITD signaling,
    such as through CXCL12/CXCR4 interactions, conferring resistance to the clinically
    available FLT3 inhibitors. (B) Concomitant inhibition of CXCR4 (plerixafor), Pi3K
    (Pi3K inhibitors: BKM-120, IPI-145, BYL-719), MEK/ERK (PD0325901, trametinib,
    MEK-162, E6201), AKT/mTOR (mTOR inhibitors: CCI-779, everolimus), NF-κB inhibitors
    (early clinical trials), PiM-kinase inhibitors (early clinical trials), and FLT3
    produces a synergistic effect in sorafenib-resistant cell lines.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CXCL11
  - STAT5B
  - CXCL13
  - CXCL5
  - CXCL12
  - CXCL8
  - CXCL6
  - PIK3R4
  - PIK3CA
  - PIK3CB
  - CXCL14
  - SHC4
  - SHC3
  - PPBP
  - PIK3R5
  - PIK3CD
  - CXCL1
  - SHC1
  - STAT5A
  - MAP2K2
  - MTOR
  - CXCL2
  - PIK3R6
  - SHC2
  - AKT3
  - CXCL3
  - CXCR4
  - AKT1
  - AKT2
  - NRAS
  - NFKB1
  - MAPK3
  - MAPK1
  - PIM1
  - FLT3
  - CXCL9
  - PF4
  - KRAS
  - BRAF
  - PIK3CG
  - PIK3R3
  - RAF1
  - CXCL10
  - HRAS
  - ARAF
  - MAP2K1
  - PD0325901
  - trametinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL11
  entrez: '6373'
- word: STAT5
  symbol: STAT5
  source: bioentities_symbol
  hgnc_symbol: STAT5B
  entrez: '6777'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL13
  entrez: '10563'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL5
  entrez: '6374'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL6
  entrez: '6372'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL14
  entrez: '9547'
- word: CXCL12
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC4
  entrez: '399694'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC3
  entrez: '53358'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PPBP
  entrez: '5473'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL1
  entrez: '2919'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC1
  entrez: '6464'
- word: STAT5
  symbol: STAT5
  source: bioentities_symbol
  hgnc_symbol: STAT5A
  entrez: '6776'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL2
  entrez: '2920'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC2
  entrez: '25759'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL3
  entrez: '2921'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: Erk1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Erk1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: Pim-1
  symbol: PIM1
  source: hgnc_symbol
  hgnc_symbol: PIM1
  entrez: '5292'
- word: FLT3
  symbol: FLT3
  source: hgnc_symbol
  hgnc_symbol: FLT3
  entrez: '2322'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL9
  entrez: '4283'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PF4
  entrez: '5196'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL10
  entrez: '3627'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
chemicals:
- word: PD0325901
  source: MESH
  identifier: C506614
- word: trametinib
  source: MESH
  identifier: C560077
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4440880__F1
redirect_from: /figures/PMC4440880__F1
figtype: Figure
---
